Using our innovative technology platform, we are committed to developing a pipeline of food allergy product candidates that could potentially transform the care of food-allergic patients.
DBV has designed a robust clinical development program that includes ongoing clinical trials of Viaskin Peanut and Viaskin Milk as well as pre-clinical development of Viaskin Egg.
Peanut allergy is one of the most common food allergies and can cause severe, potentially fatal, allergic reactions, including anaphylaxis.
We have a comprehensive clinical research program in place for Viaskin Peanut. Two Phase III long-term studies in children ages four to 11 are ongoing, as well as two Phase III trials in patients ages one to three. DBV’s Viaskin Peanut has obtained Fast Track and Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of peanut allergy in children ages four to 11.
Cow’s Milk Protein Allergy (CMPA) mainly appears in the first year of life and affects approximately 2-3 percent of the population in developed countries.
We recently completed a Phase I/II trial to study the safety and efficacy of Viaskin Milk in pediatric and adolescent patients. Viaskin Milk was granted U.S. FDA Fast Track designation in September 2016 for patients ages two to 17
Hen’s egg allergy is one of the most common food allergies in children. Several global studies suggest that egg allergy affects 1.5 – 3 percent of young children.
In the first half of 2015, DBV began pre-clinical work for Viaskin Egg, with the goal of initiating a clinical program if these studies are successful. Preclinical development is currently ongoing.
Investigations Beyond Food Allergies
DBV is investigating other areas of significant unmet medical need, including Eosinophilic Esophagitis (EoE), vaccines, inflammatory conditions and autoimmune diseases.
As we focus on diversifying our pipeline, we are also exploring the use of our technology platform in the development of diagnostic tools for food allergies. In 2016, DBV entered an exclusive global collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use and standardized atopy patch test tool for the potential diagnosis of CMPA in infants and toddlers.